Affiliations: [a] Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran | [b] Molecular Medicine Department, Pasteur Institute of Iran, Tehran, Iran
Correspondence:
[*]
Corresponding author: Reza Mahdian, Molecular Medicine Department, Pasteur Institute of Iran (IPI), No. 69, 12th Farwardin Ave, Tehran, Post Code: 1316943551, Iran. Tel./Fax: +98 21 64112439; E-mail:[email protected]
Abstract: OBJECTIVES: The ectopic expression of coagulation Factor VII has
been shown in various cancers. Recently, F7 gene has been identified as a
direct target of the androgen receptor in breast cancer. In this study, we
examined the mRNA expression of F7 and AR in clinical sample series of prostate
cancer and BPH.
MATERIAL AND METHODS: All the prostate cancer patients were new
cases with no medical history of surgery or chemotherapy. The tissue samples
were assigned as either prostate cancer tumor (n= 45) harboring at least
80% tumor cell content, or BPH (n= 36). Relative AR and F7 mRNA expression in
each tissue sample was normalized to the mean of the Ct values determined
for GAPDH and PSA genes.
RESULTS: Mean plasma level of prostate specific antigen (PSA) was
17.82 ± 3.71 ng/ml and 7.71 ± 1.28 ng/ml (Mean ± SEM) in PCa and
BPH group, respectively. AR mean expression was up-regulated 22.468
fold in clinical tumor sample cohort (S.E., 0.175-2,916, 95% CI: 0.001-126,764, P= 0.001). The mean expression of F7 gene in tumor tissues relative
to PBH samples was 6.981 (S.E., 0.099-413.001, 95% CI: 0.002-34,183, P= 0.012). ANOVA analysis of the gene expression results showed significant
correlation between F7 and AR mRNA expression in tumor samples (p< 0.001).
CONCLUSIONS: Our study findings suggest a link between FVII and AR
in prostate cancer pathogenesis. F7 gene expression could be up-regulated via various AR mediators affecting the promoter region of the F7
gene. Should this be confirmed by further studies, it may be suggested as a
potential contributing factor in prostate cancer.
